These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29252123)

  • 21. Patient-Perceived Lack of Choice in Receipt of Radioactive Iodine for Treatment of Differentiated Thyroid Cancer.
    Wallner LP; Reyes-Gastelum D; Hamilton AS; Ward KC; Hawley ST; Haymart MR
    J Clin Oncol; 2019 Aug; 37(24):2152-2161. PubMed ID: 31283406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
    Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radioactive iodine ablation therapy reduces the risk of recurrent disease in pediatric differentiated thyroid carcinoma.
    Toraih E; Webster A; Pineda E; Pinion D; Baer L; Persons E; Herrera M; Hussein M; Kandil E
    Surg Oncol; 2024 Oct; 56():102120. PubMed ID: 39154543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic Myeloid Leukemia following Exposure to Radioactive Iodine (I131): A Systematic Review.
    Ali Hailan YM; Al-Dubai HN; Yassin MA
    Oncology; 2023; 101(6):362-368. PubMed ID: 37231874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
    Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant radioactive iodine use among differentiated thyroid cancer patients in the military health system.
    Gill AA; Enewold L; Zahm SH; Shriver CD; Zheng L; McGlynn KA; Zhu K
    Mil Med; 2014 Sep; 179(9):1043-50. PubMed ID: 25181724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.
    van Velsen EFS; Visser WE; van den Berg SAA; Kam BLR; van Ginhoven TM; Massolt ET; Peeters RP
    Thyroid; 2020 Apr; 30(4):580-587. PubMed ID: 31928168
    [No Abstract]   [Full Text] [Related]  

  • 28. Radioactive iodine in differentiated thyroid cancer: a national database perspective.
    Orosco RK; Hussain T; Noel JE; Chang DC; Dosiou C; Mittra E; Divi V; Orloff LA
    Endocr Relat Cancer; 2019 Oct; 26(10):795-802. PubMed ID: 31443087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Appropriate dosing of adjuvant radioactive iodine for differentiated thyroid cancer.
    Bohinc BN; Perkins JM
    Curr Opin Oncol; 2014 Jan; 26(1):31-5. PubMed ID: 24225414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
    Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ
    Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer.
    Sun Y; Gong J; Guo B; Shang J; Cheng Y; Xu H
    Oral Oncol; 2018 Dec; 87():152-157. PubMed ID: 30527231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
    Suman P; Wang CH; Abadin SS; Block R; Raghavan V; Moo-Young TA; Prinz RA; Winchester DJ
    Endocr Pract; 2016 Jul; 22(7):822-31. PubMed ID: 27018620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of life impact of external beam radiotherapy for advanced thyroid carcinoma.
    Gal TJ; Streeter M; Burris J; Kudrimoti M; Ain KB; Valentino J
    Thyroid; 2013 Jan; 23(1):64-9. PubMed ID: 22971127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioactive Iodine-Related Clonal Hematopoiesis in Thyroid Cancer Is Common and Associated With Decreased Survival.
    Boucai L; Falcone J; Ukena J; Coombs CC; Zehir A; Ptashkin R; Berger MF; Levine RL; Fagin JA
    J Clin Endocrinol Metab; 2018 Nov; 103(11):4216-4223. PubMed ID: 30137527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study.
    Wu W; Li S; Xu K; Meng Z
    Endokrynol Pol; 2023; 74(3):260-270. PubMed ID: 37335064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer Risk After Radioactive Iodine Treatment for Hyperthyroidism: A Systematic Review and Meta-analysis.
    Shim SR; Kitahara CM; Cha ES; Kim SJ; Bang YJ; Lee WJ
    JAMA Netw Open; 2021 Sep; 4(9):e2125072. PubMed ID: 34533571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients.
    Castagna MG; Cevenini G; Theodoropoulou A; Maino F; Memmo S; Claudia C; Belardini V; Brianzoni E; Pacini F
    Eur J Endocrinol; 2013 Jul; 169(1):23-9. PubMed ID: 23594687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
    Yang Z; Flores J; Katz S; Nathan CA; Mehta V
    Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LATERAL NECK DISSECTION FOR AGGRESSIVE VARIANTS OF WELL-DIFFERENTIATED THYROID CANCER.
    Lombardi D; Taboni S; Paderno A; Giordano D; Bertagna F; Albano D; Barbieri V; Spriano G; Mercante G; Piana S; Bellafiore S; Cappelli C; Nicolai P
    Endocr Pract; 2019 Apr; 25(4):328-334. PubMed ID: 30995431
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
    Iizuka Y; Katagiri T; Ogura K; Mizowaki T
    Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.